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Abstract
Oxidative stress-modulated signaling pathways have been implicated in carcinogenesis and therapy resistance. The lens
epithelium derived growth factor p75 (LEDGF/p75) is a transcription co-activator that promotes resistance to stress-induced
cell death. This protein has been implicated in inflammatory and autoimmune conditions, HIV-AIDS, and cancer. Although
LEDGF/p75 is emerging as a stress survival oncoprotein, there is scarce information on its expression in human tumors. The
present study was performed to evaluate its expression in a comprehensive panel of human cancers. Transcript expression
was examined in the Oncomine cancer gene microarray database and in a TissueScan Cancer Survey Panel quantitative
polymerase chain reaction (Q-PCR) array. Protein expression was assessed by immunohistochemistry (IHC) in cancer tissue
microarrays (TMAs) containing 1735 tissues representing single or replicate cores from 1220 individual cases (985 tumor and
235 normal tissues). A total of 21 major cancer types were analyzed. Analysis of LEDGF/p75 transcript expression in
Oncomine datasets revealed significant upregulation (tumor vs. normal) in 15 out of 17 tumor types. The TissueScan Cancer
Q-PCR array revealed significantly elevated LEDGF/p75 transcript expression in prostate, colon, thyroid, and breast cancers.
IHC analysis of TMAs revealed significant increased levels of LEDGF/p75 protein in prostate, colon, thyroid, liver and uterine
tumors, relative to corresponding normal tissues. Elevated transcript or protein expression of LEDGF/p75 was observed in
several tumor types. These results further establish LEDGF/p75 as a cancer-related protein, and provide a rationale for
ongoing studies aimed at understanding the clinical significance of its expression in specific human cancers.
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Introduction
A growing body of evidence supports the central hypothesis that
an augmented state of cellular oxidative stress (ASCOS) is a major
contributing factor to carcinogenesis [1,2]. Possible triggers of
ASCOS include lifestyle and environmental-related factors such as
diet, infections, cigarette smoking, alcohol, and pollutants [3].
ASCOS causes damage to DNA, protein, and lipids, as well as
activation of stress transcription factors, leading to the activation of
stress, antioxidant, inflammatory, and pro-survival pathways that
contribute to malignant transformation, cell cycle deregulation,
resistance to cell death and therapy, invasion, angiogenesis, and
metastasis [1,2].
LEDGF/p75 is a stress response protein that promotes cell
survival in the presence of environmental stressors that induce
ASCOS, such as chemotherapy, radiation, heat, and serum
starvation [4–7]. LEDGF/p75 is also known as transcription co-
activator p75 [8], PC4 and SFRS1 interacting protein (PSIP1) [9],
and dense fine speckled autoantigen of 70 kD (DFS70) [10]. It has
been implicated in inflammation, autoimmunity, HIV-1 replica-
tion, and cancer [10–17]. The stress survival properties of
LEDGF/p75 appear to be linked to its ability to bind specific
transcription factors and facilitate the transactivation of stress,
inflammatory, antioxidant, and cancer-associated genes [18–23].
LEDGF/p75 (530 amino acids) and its less characterized
alternative splice variant, LEDGF/p52 (333 amino acids), are
derived from the LEDGF/PSIP1 gene [8,9,24]. LEDGF/p52
corresponds to N-terminal amino acids 1–325 of LEDGF/p75,
and contains an additional intron-derived 8 amino-acid tail [25].
Our group reported previously that LEDGF/p75 is upregulated in
cancer cells compared to normal cells, and that LEDGF/p52 is
expressed at relatively low levels in cancer cells, induces apoptosis
when ectopically expressed, and antagonizes the pro-survival
functions of LEDGF/p75 [7,16,25].
Several lines of evidence support the recent emergence of
LEDGF/p75 as an oncoprotein in human cancer. For instance,
LEDGF/p75 is a target of chromosomal translocations in
leukemias, resulting in LEDGF/NUP98 fusion proteins with
enhanced activity [23,26–29]. Its mRNA expression was found to
be upregulated in blasts from chemotherapy-resistant acute
myelogenic leukemia patients, and its ectopic overexpression
protected leukemia cells against drug-induced cell death [30].
LEDGF/p75 tethers the menin-mixed lineage leukemia (MLL)
transcription factor complex to chromatin to activate leukemo-
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an autoantigen in prostate cancer (PCa), with elevated protein
expression in prostate tumor tissues [16]. We also observed that its
ectopic overexpression promoted cellular survival against stress-
induced death in HepG2 liver tumor cells [7], and attenuated
docetaxel-induced lysosomal cell death in PCa cells [31].
Daugaard et al. [17] reported elevated LEDGF/p75 transcript
expression in human breast and bladder cancers, and that its
ectopic overexpression in breast cancer cells protected against
drug-induced lysosomal cell death and increased the tumorigenic
potential of the cancer cells in murine models. Recently, elevated
gonadotropins were shown to enhance LEDGF/p75-dependent
activation of VEGF-C expression, augmenting lymphangiogenesis
and angiogenesis of ovarian tumors [32].
Although the transcript expression of LEDGF/p75 was
reported to be upregulated in leukemia, breast, and bladder
cancers [17,30], immunohistochemical (IHC) expression analysis
of the protein in human tumor tissues has been performed only for
PCa [16]. The emerging role of LEDGF/p75 as a stress survival
oncoprotein led us to undertake a comprehensive analysis of its
mRNA and protein expression in 21 major human tumor types,
using cancer gene microarray databases, TissueScan Cancer Q-
PCR array, and IHC analysis of tissue microarrays (TMAs). This
study provides evidence that LEDGF/p75 is selectively upregu-
lated in human cancers.
Materials and Methods
Bioinformatics Analysis of Oncomine Cancer Gene
Microarray Database
For comparison of LEDGF mRNA expression between tumor
and normal tissues, we selected datasets from the Oncomine
database (Compendia Biosciences; Ann Arbor, MI, USA; www.
oncomine.org). These datasets, containing gene microarrays of
cancers and corresponding disease-free normal and/or normal
adjacent tissues, provided fold-change data for gene expression
(tumor vs normal), with p-values calculated by t-tests. It should be
mentioned that the datasets examined were not specific for
LEDGF/p75 but provided gene expression data for the LEDGF/
PSIP1 gene, which gives rise to both the p75 and p52 splice
variants. A total of 81 datasets were examined for LEDGF/PSIP1
transcript expression for the following cancers: bladder (2 datasets),
breast (9 datasets), cervix (2 datasets), colon and rectum (3
datasets), esophagus (3 datasets), kidney (6 datasets), head and neck
(8 datasets), liver (2 datasets), lung (9 datasets), lymphoma (3
datasets), ovary (6 datasets), pancreas (6 datasets), prostate (13
datasets), salivary gland (1 dataset), skin (5 datasets), stomach (2
datasets) and uterus (1 dataset). No microarray data was available
for LEDGF/PSIP1 transcript expression in cancers of the gall
bladder, small intestine, and thyroid.
Human ‘TissueScan Cancer Survey Panel’ Q-PCR Array
We used the human ‘TissueScan Cancer Survey Panel 96–I’ Q-
PCR array (CSRT-101, OriGene Technologies Inc., Rockville,
MD, USA) for in-house analysis of LEDGF/p75 mRNA
expression in 96 tissues covering 8 major human cancers (breast,
colon, kidney, liver, lung, ovarian, prostate, and thyroid). This
array consisted of first-strand complementary DNA (cDNA) from
9 individual cases of each cancer type and 3 cases of corresponding
normal adjacent tissues. The manufacturer provided limited
patient clinicopathological information (age, sex, tumor stage,
pTNM stage), with no patient identifiers.
Q-PCR was performed in 96-well PCR array plates (OriGene)
using the MyiQ thermal cycler (Bio-Rad Laboratories, Hercules,
CA, USA) with primers specific for the LEDGF/p75 splice variant
(forward 59-TGCTTTTCCAGACATGGTTGT-39 and reverse
59-CCCACAAACAGTGAAAAGACAG-39), and iQ SYBR
Green Supermix (Bio-Rad). Briefly, 30 ml of PCR mixture, which
included 15 mlo f2 6master mix, 13 ml of double distilled water,
and 1 ml each of forward and reverse primers (10 pmol/ml), were
added to each of the 96 wells of the PCR array plates. PCR
amplification was conducted at 95uC for 10 minutes, followed by
40 cycles of 95uC for 15 seconds and 60uC for 1 minute. mRNA
expression was normalized using the expression of housekeeping
gene human beta-actin, whose primers (forward 59-CAGCCATG-
TACGTTGCTATCCAGG-39 and reverse 59-AGGTCCA-
GACGCAGGAT GGCATG-39) were provided in the TissueScan
Cancer Q-PCR array kit at a concentration of 10 pmol/ml. For
data analysis, the DDCt method was used. Fold changes were
calculated as the difference in gene expression between tumors and
corresponding normal adjacent controls.
RNA Interference-mediated Knockdown of LEDGF/p75
PC-3 prostate cancer cells were purchased from American Type
Culture Collection and cultured as recommended by the supplier
in a humidified incubator with 5% CO2 at 37uC. Transient
knockdown of LEDGF/p75 in PC-3 cells was carried out using the
Amaxa Nucleofection method (Amaxa, Lonza) as described
previously [21]. LEDGF/p75 siRNA (siLEDGF/p75) and the
scrambled siRNA duplex (siSD, negative control) were synthesized
by Integrated DNA Technologies (IDT). The siLEDGF/p75
sequence corresponded to nucleotides 1340–1360 (59- AGACAG-
CAUGAGGAAGCGAdTdT-39) with respect to the first nucleo-
tide of the start codon of the LEDGF/p75 open reading frame
[21]. This sequence corresponds to a region in the C-terminus of
LEDGF/p75 not shared by LEDGF/p52. The sequence for siSD
was 59- GCGCGCUUUGUAGGAUUCGdTdT-39 [21].
Antibodies and Immunoblotting
The following antibodies were used: mouse monoclonals anti-b-
actin (Sigma-Aldrich), and anti-LEDGF (1:1000, BD Biosciences);
rabbit polyclonals anti-LEDGF/p75 (1:1000, Novus Biologicals);
anti-LEDGF/p75 (1:1000, Bethyl); and horseradish peroxidase
(HRP)-labeled secondary IgG antibodies (Zymed). We also used a
LEDGF/p75-specific rabbit polyclonal antibody that was devel-
oped at the W.M. Keck Autoimmune Disease Center of The
Scripps Research Institute (La Jolla, CA, USA). This rabbit
antibody, originally designated anti-DFS/LEDGFp75#5087 an-
tibody (hereafter referred to as Scripps-Ab5087), was raised against
a recombinant, truncated DFS70 protein generated from a partial
cDNA clone, pDFS6.1, which encoded the C-terminal region of
LEDGF/p75 [10]. To identify an antibody that is specific only for
the LEDGF/p75 splice variant, we examined the reactivity of all
the above-mentioned commercial and non-commercial LEDGF
antibodies by immunoblotting using cell lysates from PC-3 cells
with siSD and siLEDGF/p75.
Immunoblotting was carried out essentially as described
previously [21]. Briefly, total proteins from PC3 cells with siSD
and siLEDGF/p75 were separated by SDS-PAGE (NuPAGE 4–
12%, Invitrogen) followed by transfer to polyvinyl difluoride
(PVDF) membranes (Millipore). Membranes were blocked with
5% dry milk solution in TBS-T buffer (20 mM Tris-HCl, pH 7.6,
140 mM NaCl, 0.1% Tween 20) for 1 h and probed with primary
antibodies. After several washes with TBS-T, membranes were
incubated with horseradish peroxidase (HRP)-conjugated second-
ary antibodies for 30 minutes and then washed again with TBS-T.
Protein bands were detected by enhanced chemiluminescence
(Amersham).
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Microarrays
Human cancer tissue microarrays (TMAs), commercially
available from National Disease Research Interchange (NDRI,
Philadelphia, PA, USA), Imgenex Corp. (San Diego, CA, USA)
and US Biomax Inc. (Rockville, MD, USA), were used for IHC
analysis of LEDGF/p75. Several different TMAs were used to
increase the number of tumor tissue types and sample size
(Table 1). Briefly, we acquired NDRI’s comprehensive pan-cancer
TMAs containing duplicate cores of 642 unique cases (522 tumor
tissues of 20 major tumor types and 120 disease-free normal and/
or normal adjacent specimens) in a 5 slide set (TS-1, TS-2, TS-3,
TS-4 and TMA5). Each of pan-cancer TMAs IMH-326, IMH-
327 and IMH-328 (Imgenex Corp), contained 59 specimens of
various tumor types, while TMAs IMH-336, IMH-337 and IMH-
338 (Imgenex Corp.) contained the corresponding 59 matched
normal adjacent tissues.
We also used TMA IMH-303 (Imgenex Corp.), containing 40
PCa tissues and 9 matched normal adjacent tissues. Eight
additional TMAs from US Biomax were used, each containing
multiple tissue specimens of a single tumor type (breast, colon,
kidney, lung, liver, pancreas, prostate, thyroid) as well as
corresponding disease-free normal control and/or normal adja-
cent tissues. The manufacturers of these TMAs provided limited
basic clinicopathological information (age, sex, tumor stage in
some cases) corresponding to the tissue cores, with no patient
identifiers. No information was available on patient race or
ethnicity, neo-adjuvant treatment, surgical technique, year of
surgery, institutions that collected the tissues, number of
institutions, follow up routines, and tissue handling techniques.
The limited patient follow up data associated with the TMAs
prevented any Kaplan-Meier survival analysis.
TMAs were stained using a Biogenic i6000 auto-stainer
(Biogenex Corporation, Fremont, CA, USA) as described
previously [16,33]. Briefly, paraffin embedded tissue sections in
the TMA slides were deparaffinized and the slides were immersed
in Citra-Plus antigen retrieval solution (Biogenex Corp.). Antigen
retrieval was performed by microwaving the slides for 2 min at
100% power followed by 10 min at 20% power. Slides were then
cooled in the antigen retrieval solution for 20 min. Endogenous
peroxidase activity was quenched by treatment with 3% hydrogen
peroxide in 10% methanol, and Power Block universal blocking
reagent (Biogenex Corp.) was used to block non-specific protein
binding.
TMA slides were incubated overnight with Scripps-Ab5087
anti-LEDGF/p75 antibody [16], followed by 3 washes in PBS.
Slides were then incubated with Multi-link biotinylated
secondary antibody (Biogenex Corp.) for 20 minutes, followed
by incubation with streptavidin-coupled peroxidase supersensitive
Label (Biogenex Corp.) for 20 min. Immunostaining was
detected by peroxidase activation of the 3-amino-9-ethycarbazole
(AEC) chromagen (Biocare Medical, Concord, CA, USA). TMAs
were counterstained lightly with hematoxylin (Sigma, St. Louis,
MO, USA) and mounted with permount (Fisher Scientific,
Pittsburgh, PA, USA). For negative control the primary antibody
was omitted and substituted with rabbit pre-immune serum.
Tissue sections were examined under an Olympus BX50
microscope, and images were acquired using a digital Spot
RT3
TM camera (Diagnostic Instruments, Sterling Heights, MI,
USA). Immunostained TMAs were scored blindly for LEDGF/
p75 immunoreactivity by a board certified pathologist. A 4-tier
scoring system (0=negative, 1=weak, 2=moderate, 3=strong)
was used to evaluate staining intensity. Tissues with scores of 0–1
were considered to have low intensity staining, whereas tissues
with scores of 2–3 were considered to have high intensity staining.
Tissue specimens that showed poor quality were excluded from the
analyses. These studies were performed under approval by the
Institutional Review Board.
Statistical Analysis
The student’s t-test was used to evaluate the significance of the
change in mRNA expression between the tumor and normal
adjacent control samples in the TissueScan Cancer Q-PCR array.
Statistical analysis of IHC data and their relationship to patients’
clinical outcomes was done using the SAS software package
(version 9.2; SAS institute). For ease of statistical analysis, tissue
specimens were grouped into two categories based on their scores.
‘Low’ staining was determined as pooled staining intensity scores
of 0 and 1 while ‘high’ staining had pooled scores of 2 and 3.
Difference in expression levels of LEDGF/p75 protein between
tumors and normal tissues were analyzed using Fisher’s exact test.
To control for false positives, which may arise in multiple-
hypotheses-testing studies, false discovery rate (FDR) adjusted p-
values were also calculated. FDR is a quantification of error used
commonly in multiple comparisons. It controls the expected
proportion of incorrectly rejected null hypotheses. In other words,
FDR controls the fraction of positive detections that are false.
Associations between expression levels of LEDGF/p75 and
clinicopathological parameters were determined using Fisher’s
exact test (for age and sex) and Kendall’s tau correlation analysis
(for tumor stage). Probability values P,0.05 were considered
statistically significant. Reproducibility of replicate cores was
assessed by Cochran-Mantel-Haenszel test which tested for
homogeneity between the replicates.
Results
LEDGF/p75 transcript is upregulated in various human
cancer types
In silico analysis of LEDGF/PSIP1 mRNA expression in cancer
tissues was carried out using cancer gene microarray datasets from
the Oncomine database that compared cancer tissues to normal
tissues (either disease-free normal and/or normal adjacent). As
summarized in Table 2, we observed a statistically significant
(P,0.05) upregulation of LEDGF/PSIP1 transcript in some of the
available microarray datasets from cancers of the breast, cervix,
colon, esophagus, kidney, head and neck, liver, lung, lymphoma,
ovary, pancreas, prostate, salivary gland, skin, and stomach. The
fold-increase was greater than 2 in cancers of the breast, cervix,
head and neck, kidney, skin, and stomach (Table 2). The increase
was modest (between 1 and 2) in colorectal, esophageal, liver, lung,
ovarian, pancreatic, prostate, and salivary gland cancers. No
changes in LEDGF/PSIP1 transcript expression were detected in
bladder (5 datasets) and uterine (1 dataset) cancers. None of the
above-mentioned 17 cancer types showed significant downregula-
tion of LEDGF/PSIP1 transcript in any dataset. No datasets were
available comparing tumor vs normal expression of LEDGF/PSIP1
transcript in gall bladder, small intestine, and thyroid cancers.
The expression of LEDGF/p75 transcript was further assessed
experimentally in eight solid tumor types (breast, colon, kidney,
liver, lung, ovarian, prostate and thyroid) using the TissueScan
Cancer Q-PCR array, which contained cancer tissue samples from
12 individual donor cases (n=9 for each cancer type, n=3 for
corresponding normal tissues). Primers specific for LEDGF/p75
were used in these experiments. As shown in Figure 1, a
statistically significant (P,0.05) upregulation of LEDGF/p75
transcript was observed in prostate (2.38 fold, P=0.002), thyroid
(1.85 fold, P=0.031), breast (2.26 fold, P=0.037) and colon (2.04
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TMA Source Description Tissue type # of # of Total #
cases cores of tissues
TMAs with tumor tissues
TS-1 NDRI Pan-cancer Breast, ovarian, endometrial, gynecological 125 250 250
tumors
TS-2 NDRI Pan-cancer Lung, head and neck, colorectal, stomach, 139 278 278
pancreatic tumors
TS-3 NDRI Pan-cancer Bladder, kidney, prostate, testes tumors 129 258 258
TS-4 NDRI Pan-cancer Endocrine tumors including thyroid, 129 258 258
lymphomas, sarcomas, melanomas
IMH- Imgenex Pan-cancer Stomach, esophagus, lung, colorectal, 59 59 59
326 thyroid, kidney tumors
IMH- Imgenex Pan-cancer Breast, liver, bladder, ovary, pancreas, 59 59 59
327 prostate tumors
IMH- Imgenex Pan-cancer Tumors of uterus, gall bladder, larynx, 59 59 59
328 uterine cervix, malignant lymphoma,
TMAs with normal tissues
TMA-5 NDRI Pan-normal Normal tissues corresponding to TS1-4 120 240 240
IMH- Imgenex N. Adj of Stomach, esophagus, lung, colorectal, 59 59 59
336 IMH-326 thyroid, kidney normal
IMH- Imgenex N. Adj of Breast, liver, bladder, ovary, lymph node, 59 59 59
337 IMH-327 pancreas, prostate, uterus, spleen
IMH- Imgenex N. Adj of Uterus, gall bladder, larynx, uterine cervix, 58 58 58
338 IMH-328 lymph node, colon, vagina, ovary, muscle
TMAs with tumor and normal tissues
IMH- Imgenex Tumor and Prostate tumor 40 40 49
303 N. Adj Prostate normal 9 9
PR- Biomax Tumor, Prostate tumor 50 50 80
807 N. Adj and Prostate normal 10 10
Hyperplasia Prostate hyperplasia 20 20
BR- Biomax Tumor and Breast tumors 78 78 80
803 N. Adj Breast normal 2 2
CO- Biomax Tumor and Colorectal tumor 81 81 100
1002 N. Adj Colorectal normal 19 19
LUC- Biomax Tumor, Lung tumor 36 72 96
961 N. Adj and Lung normal 4 8
Inflammation Lung inflammatory 8 16
LVC- Biomax Tumor, Liver tumor 36 72 96
961 N. Adj and Liver normal 3 6
Inflammation Liver inflammatory 9 18
KD- Biomax Tumor and Kidney tumor 40 40 48
483 N. Adj Kidney normal 8 8
PA- Biomax Tumor and Pancreas tumor 40 40 48
483 N. Adj Pancreas normal 8 8
THC- Biomax Tumor, Thyroid tumor 30 60 96
961 N. Adj and Thyroid normal 3 6
Inflammation Thyroid inflammatory 15 30
doi:10.1371/journal.pone.0030132.t001
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transcript was elevated (.1.02 fold) in other cancer types (with the
exception of liver cancer) the fold changes were not statistically
significant. Liver tumors showed a slight downregulation (21.24
fold) in LEDGF/p75 transcript expression, but the decrease was
statistically insignificant.
Table 2. LEDGF/p75 transcript expression in human tumors determined by analysis of Oncomine cancer gene microarray
database.
Cancer type # of data % of up- % of down- Range fold-change Range P values
subsets regulated regulated
subsets subsets
Bladder 5 0.0 0 (21.272) to (1.224) (0.102) to (0.934)
Breast 17 11.8 0 (21.449) to (2.557) (2.29E-18) to (0.956)
Cervix 3 33.3 0 (1.023) to (4.441) (3.25E-09) to (0.18)
Colorectal 10 30.0 0 (21.027) to (1.287) (0.002) to (0.955)
Esophagus 6 16.7 0 (21.266) to (1.858) (0.019) to (0.884)
Kidney 14 28.6 0 (22.521) to (3.512) (0.001) to (0.944)
Head and neck 12 25.0 0 (21.124) to (3.692) (0.001) to (0.995)
Liver 2 50.0 0 (1.043) to (1.38) (4.15E-5) to (0.265)
Lung 17 11.8 0 (1.89E-06) to (1.00) (21.651) to (5.2)
Lymphoma 11 9.1 0 (0.014) to (0.67) (21.093) to (2.857)
Ovary 12 8.3 0 (22.976) to (1.529) (3.61E-06) to (1.00)
Pancreas 6 16.7 0 (21.033) to (1.748) (0.008) to (0.57)
Prostate 13 7.7 0 (21.88) to (1.272) (0.017) to (1.00)
Salivary gland 1 100.0 0 1.634 0.001
Skin 10 40.0 0 (21.392) to (2.014) (4.67E-06) to (0.859)
Stomach 6 66.7 0 (1.032) to (2.871) (4.34E-08) to (0.309)
Uterus 1 0.0 0 21.051 0.617
*P,0.05.
doi:10.1371/journal.pone.0030132.t002
Figure 1. Transcript expression of LEDGF/p75 in eight human cancer types determined by TissueScan Cancer Q-PCR analysis. Data
were analyzed using the DDCt method with values normalized to b-actin levels. The y-axis represents the induction fold of the LEDGF/p75 mRNA
level in eight cancer types (n=9) compared to matching normal adjacent tissues (n=3) in the array. Error bars displays the range of standard error.
* P,0.05. P values were determined with Student’s t-test.
doi:10.1371/journal.pone.0030132.g001
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In order to identify an antibody that is specific for LEDGF/p75
and that could be used by IHC to assess the expression levels of
this protein in cancer TMAs, we evaluated by immunoblotting the
specificity of currently available anti-LEDGF antibodies. Three
commercially available anti-LEDGF antibodies (Bethyl, BD and
Novus) and a non-commercial antibody (Scripps-Ab5087) against
LEDGF were tested by immunoblotting in PC-3 cells with and
without transient knockdown of the protein (Figure 2). PC-3 cells
transfected with siSD served as control. Immunoblotting analysis
indicated that all the 3 commercial antibodies to LEDGF reacted
with both p75 and p52 variants. However, the Scripps-Ab5087
Figure 2. Identification of LEDGF/p75 specific antibody by immunoblotting in PC-3 cells with transient LEDGF/p75 knockdown.
Cells were transfected with siLEDGF/p75 to induce transient knockdown of LEDGF/p75. PC-3 cells transfected with small interfering scrambled RNA
duplex (siSD) served as corresponding control. Immunoblotting analysis tested the specific reactivity of all the antibodies against LEDGF/PSIP1. All the
blot pairs (siSD and siLEDGF/p75) for each antibody were derived from the same blot.
doi:10.1371/journal.pone.0030132.g002
Table 3. Differential expression of LEDGF/p75 protein analyzed by immunohistochemistry in 21 human tumor types and
corresponding normal tissues.
Cancer Type Tumor Tumor scores (%) Normal Normal scores % P
tissue # low high tissue # low high value
Bladder 55 92.7 7.3 6 83.3 16.7 0.929
Breast 220 79.5 20.5 11 100.0 0.0 0.087
Cervix 10 50.0 50.0 4 100.0 0.0 0.126
Colon 148 75.0 25.0 32 93.8 6.3 0.012
Esophagus 10 80.0 20.0 9 22.2 77.8 0.999
Gall bladder 10 90.0 10.0 9 77.8 22.2 0.913
Kidney 122 75.4 24.6 17 70.6 29.4 0.772
Head and neck 17 94.1 5.9 8.0 100.0 0.0 0.680
Liver 100 32.0 68.0 16 68.8 31.3 0.006
Lung 164 44.5 55.5 18 55.6 44.4 0.259
Lymphoma 60 85.0 15.0 11 100.0 0.0 0.199
Ovary 76 80.3 19.7 7 100.0 0.0 0.234
Pancreas 105 59.0 41.0 22 54.5 45.5 0.736
Prostate 115 61.7 38.3 30 100.0 0.0 0.000
Rectum and anus 7 71.4 28.6 6 50.0 50.0 0.914
Salivary gland 7 71.4 28.6 1 100.0 0.0 0.750
Skin 64 81.3 18.8 6 100.0 0.0 0.309
Small Intestine 5 100.0 0.0 1 100.0 0.0 n/a
Stomach 37 94.6 5.4 13 100.0 0.0 0.544
Thyroid 105 29.5 70.5 16 87.5 12.5 0.000
Uterus 43 69.8 30.2 12 100.0 0.0 0.025
TMAs stained with antibody against LEDGF/p75 were scored as: 0=no staining, 1=low, staining, 2=moderate staining, 3=strong staining. Scored tissues were pooled
in two groups: low staining (scores 0 and 1) and high staining (scores 2 and 3). P values comparing the immunohistochemical expression (high vs. low) of LEDGF/p75
protein between tumor tissues and corresponding normal tissues was determined using the Fisher’s exact test. Bold numbers denote significant P values. n/a-Not
applicable.
doi:10.1371/journal.pone.0030132.t003
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for IHC studies.
LEDGF/p75 Protein is Overexpressed in Various Human
Cancer Types
We performed IHC analysis of LEDGF/p75 protein expression
in tumor tissues using a comprehensive panel of TMAs containing
a total of 2330 tissue cores, including 1754 tumors tissue cores
from over 35 major types of human cancer and corresponding 576
non-tumor (normal and non-cancerous inflammatory) tissue cores
(Table 1). We excluded from our statistical analysis those tumor
types which had ,5 tumor tissue cores or/and had no
corresponding non-tumor tissues. The non-tumor inflammatory
tissue cores were also excluded because not all tumor types had the
corresponding inflammatory tissues. Some tissue cores could not
be scored due to poor tissue quality. In the end, 21 tumor types
were included in our statistical analysis (Table 3). These comprised
a total of 1735 tissues representing single or replicate cores from
1220 individual donor cases, with 985 tumor cases and 235 non-
tumor cases.
The results from the IHC analysis of pooled scores for
LEDGF/p75 protein expression (i.e., high=scores 2–3 vs
low=scores 0–1) in tumor tissues compared to normal tissues
are shown in Table 3. There was significant overexpression of the
LEDGF/p75 protein in prostate, colon, thyroid, liver, and
uterine tumors (P,0.05) (Table 3 and Figure 3). Elevated
expression levels in breast tumors came close to statistical
significance (P=0.087). When corrected for occurrence of false
positives, only prostate, thyroid, and liver tumors were found to
exhibit significant overexpression of LEDGF/p75 protein (FDR
adjusted P,0.05).
The percentage of tumor tissues with high (scores 2–3) LEDGF/
p75 protein expression was 70.5% in thyroid, 68% in liver, 38.3%
in prostate, 30.2% in uterine, and 25% in colon cancers, as
compared to 12.5%, 31.3%, 0%, 0%, and 6.3%, respectively, in
their corresponding normal tissues (Table 3). There were four
cancer types (breast, cervix, ovary, and salivary gland) in which the
frequency of tumors displaying high LEDGF/p75 protein
expression was about 20% or greater, and the corresponding
normal tissues showed little or no expression of the protein.
However, when we compared differences in LEDGF/p75
expression (high vs. low expression) between tumor and normal
tissues, the P values did not reach significance. Interestingly, when
we compared differences between tumor and normal tissues with
regards to LEDGF/p75 expression (scores 1–3) vs no expression
(score 0), the P values for breast and cervical cancers reached
significance (P,0.05; data not shown). Comparison of the
replicate cores showed no significant difference (P=0.6226)
between the replicates, suggesting high reproducibility between
the replicate cores.
Figure 4A shows representative tumor tissue cores immuno-
stained with Scripps-Ab5087 anti-LEDGF/p75 antibody. The
representative IHC images correspond to prostate, colon, and
thyroid tumor tissue cores with low (scores 0–1) and high intensity
(scores 2–3) staining. As mentioned above, these three tumor types
displayed significant upregulation of both transcript (TissueScan
Figure 3. Elevated immunohistochemical expression of LEDGF/p75 protein in five tumor types compared to corresponding normal
tissues. Tissue microarrays were stained with antibody against LEDGF/p75, and the individual cores were blindly scored using the following scale:
0=no staining, 1=low staining, 2=moderate staining, 3=strong staining. Scored tissues were pooled into two groups: low staining (scores 0 and 1,
dark bars) and high staining (scores 2 and 3, light bars). The percentage of specimens in the two staining categories was plotted for tumor tissues
compared to normal (including disease-free normal and normal adjacent) tissues. *P,0.05; **P,0.01. P values were determined with Fisher’s exact
test.
doi:10.1371/journal.pone.0030132.g003
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representative IHC images of disease-free normal prostate and
colon tissues (from non-cancer donors), as well as prostate and
colon tumor specimens with their matched adjacent tissues. The
thyroid cancer TMAs did not have matched adjacent tissues for
specific thyroid tumors. We observed that the ‘‘normal’’ tissues
adjacent to the prostate and colon tumor tissues had moderate
LEDGF/p75 staining, compared to the relatively low intensity
staining of the disease-free normal tissues. Another interesting
observation was that LEDGFp75 immunostaining was distributed
in both the nucleus and the cytoplasm in most tumor tissues
examined.
The available clinicopathological characteristics of patients
with tumor types displaying significant LEDGF/p75 overexpres-
sion are summarized in Table 4. The number of tissue samples
for colon and prostate cancers differs in the sets discussing age
and sex because of missing data in the commercially available
TMAs. Data on age was missing for 4 cores in the prostate cancer
TMAs while data on sex was missing for 2 cores in the colon
cancer TMA. Correlation between these characteristics and
LEDGF/p75 protein expression revealed that overexpression of
this protein in liver and thyroid tumors was significantly
associated with younger age (P,0.05) (Table 4). The median
ages of patients represented in the TMAs were 62 years for colon
Figure 4. Immunohistochemical staining for LEDGF/p75 protein in selected human tumors. A. Representative images of
immunohistochemical staining (low intensity, scores 0–1; high intensity, scores 2–3) for LEDGF/p75 in prostate, colon, and thyroid tumors (Scale
bar-40 mm; magnification=2006). B. Representative images of LEDGF/p75 immunostaining of non-disease normal prostate and colon tissues, and in
tumor tissues and their matched adjacent tissues (Scale bar-40 mm; magnification=4006). TMAs were stained using LEDGF/p75 specific rabbit
antibody Scripps-Ab5087, as indicated in Materials and Methods. Identical camera settings were used in the acquisition and processing of images for
a particular tissue type.
doi:10.1371/journal.pone.0030132.g004
Expression of LEDGF/p75 in Human Cancer
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30132cancer, 53 years for liver cancer, 66 years for prostate cancer, 48
years for thyroid cancer and 70 years for uterine cancer. None of
the five tumor types exhibited significant correlation between
increased LEDGF/p75 expression, sex or increased TNM tumor
stage. The limited patient follow-up data associated with the
TMAs precluded correlating LEDGF/p75 expression with
patient survival outcomes.
The cross-platform analysis of LEDGF/p75 expression in
various human tumor types has been summarized in Table 5.
The transcript and protein expressions for each tumor type are
compared across the different platforms used: in silico, Q-PCR
and IHC.
Discussion
The present study was undertaken as part of our ongoing efforts
to understand the biological and clinical significance of LEDGF/
p75 expression in human cancer. Our results indicated significant
upregulation of both LEDGF/p75 transcript and protein in
prostate, colon, and thyroid tumors, inferred by the analysis of
transcript expression in the Oncomine cancer gene microarray
database (when data available) and the TissueScan Cancer Q-
PCR array, and analysis of protein expression by IHC in TMAs.
The observed upregulation of LEDGF/p75 in prostate tumors is
consistent with our previous reports that this protein is the target of
autoantibodies in some patients with PCa, is upregulated in both
PCa cell lines and tissues, and promotes chemoresistance in PCa
cell lines when ectopically overexpressed [16,31].
Significant upregulation of LEDGF/PSIP1 transcript was also
observed in some Oncomine datasets for cancers of the breast,
cervix, esophagus, kidney, head and neck, liver, lung, lymphoma,
ovary, pancreas, salivary gland, skin, and stomach. However, only
4 out of 8 tumor types (prostate, colon, breast and thyroid)
exhibited significant upregulation of the LEDGF/p75 transcript in
the TissueScan Cancer Q-PCR array. Although other tumor types
(kidney, lung, and ovarian) exhibited .1.02 fold LEDGF/p75
transcript elevation in this array, the upregulation was not
statistically significant. These differences between the Oncomine
database and the TissueScan Cancer Q-PCR array could be
attributed to the small sample size in the latter, methodological/
platform variations, analysis of LEDGF/PSIP1 vs LEDGF/p75,
and the use of unrelated tumor data sets.
In addition to prostate, colon and thyroid cancers, the LEDGF/
p75 protein levels were significantly elevated, as assessed by IHC
analysis of TMAs, in liver and uterine cancers. To control for false
positives, which are expected when numerous independent
statistical tests are performed, FDR analysis was done. The FDR
adjusted p-values suggested that the LEDGF/p75 protein
overexpression in prostate, thyroid, and liver tumors was not by
chance. Elevated expression of LEDGF/p75 in liver and thyroid
tumors was associated with younger age, while none of the five
tumor types displayed a significant correlation between increased
LEDGF/p75 expression and increased tumor stage, most likely
due to the relatively small number of tumor samples in stages pT1
and pT4.
An interesting observation in our IHC analysis was that
LEDGF/p75 was not exclusively confined to the nucleus, but
often appeared in the cytoplasm of tumor cells. We cannot rule out
the possibility that this could be due to non-specific reactivity of
the Scripps-Ab5087 anti-LEDGF/p75 antibody. However, this
would seem unlikely given that the antibody reacted specifically
with LEDGF/p75 in immunoblots, and the cytoplasmic staining
was not observed in all tissues, particularly in normal tissues. It
could be speculated that depending on the particular tumor
microenvironment, LEDGF/p75 could shuttle between the
extracellular milieu, the cytoplasm, and the nucleus, as observed
for other stress or survival proteins [34–36]. While there is
compelling evidence that LEDGF/p75 exhibits a nuclear
localization in cultured cell lines, early studies suggested that the
protein exists as both endogenous and secreted forms [4,37]. It
Table 4. Association of LEDGF/p75 protein expression in colon, liver, prostate, thyroid and uterine tumors with patients’ clinical
characteristics.
Characteristic Colon Liver Prostate Thyroid Uterus
# of P # of P # of P # of P # of P
tissues value tissues value tissues value tissues value tissues value
Age (years) 0.7045 0.0473 0.6646 0.0283 0.099
#Median age 78 50 57 54 18
.Median age 67 48 54 51 16
Sex 0.5606 0.9771 N/A 0.7579 N/A
Male 97 79 115 41 0
Female 46 19 0 64 34
Tumor stage 0.4476 0.9182 0.7328 0.1254 N/D N/A
pT1 2 2 2 4
pT2 17 54 34 40
pT3 34 10 45 8
PT4 9 0 6 4
Bold numbers denote significant P values. P values for the association of immunohistochemical LEDGF/p75 expression (high vs. low comparison) in tumors with
patients’ age and sex were calculated using Fisher’s exact test, while those for tumor stage were calculated using Kendall’s tau b correlation analysis. At the time of
surgical excision of the tissues, the median age of donors was 62 years for colon cancer, 53 years for liver cancer, 66 years for prostate cancer, 48 years for thyroid cancer,
and 70 years for uterine cancer. The tumor stages (pT1 to pT4) correspond to pathologic tumor stages T1 through T4 used in the TNM system of cancer staging. The
TNM system is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of distant metastasis (M). A number is addedt oe a c h
letter (eg. T1, T2, T3, T4) to indicate the size or extent of the primary tumor and the extent of cancer spread. N/A, Not applicable; N/D, No data available.
doi:10.1371/journal.pone.0030132.t004
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LEDGF/p75 is secreted from tumor cells, and if this release
provides a survival advantage to cancer cells in a stressful tumor
microenvironment.
We did not observe a statistically significant overexpression of
LEDGF/p75 protein in bladder tumors, which is inconsistent with
a previous report by Daugaard et al. [17] showing upregulation of
LEDGF/p75 mRNA in bladder tumors from Affymetrix micro-
array data. None of the 5 Oncomine bladder cancer datasets
analyzed for LEDGF/PSIP1 transcript expression showed signif-
icant upregulation. However, our data on elevated transcript
expression of LEDGF/p75 in breast tumors was in agreement
with that of Daugaard et al. [17]. Our analysis showed significant
upregulation of LEDGF/PSIP1 transcript levels in breast tumors
in 2 of the 17 Oncomine breast cancer gene microarray datasets,
and robust elevation of LEDGF/p75 transcript (2.26 fold,
P=0.037) in the TissueScan Cancer Q-PCR array. Likewise,
our evaluation of LEDGF/p75 protein levels in the breast tumor
tissues by IHC came very close to being statistical significant
(P=0.087). Daugaard et al. [17] also reported lack of LEDGF/
p75 transcript upregulation in colon cancer, whereas we found
significant transcript upregulation in 3 of 10 Oncomine colorectal
cancer datasets, and in the TissueScan Cancer Q-PCR array. Our
IHC analysis also indicated LEDGF/p75 overexpression in colon
cancer. These discrepancies between our results and those of
Daugaard et al. [17] might be related to differences in the patient
cohorts or in the methodologies/platforms used.
A limitation of the present study is that the analyses of LEDGF/
p75 transcript and protein expression were done in unrelated
tumor datasets. It should be emphasized, however, that this study
was designed to determine if LEDGF/p75 is a commonly
upregulated protein in major human cancers. Our results indicate
that LEDGF/p75 upregulation in human cancer is selective, with
statistically significant elevation of both transcript and protein in
prostate, colon, and thyroid tumors, as determined by TissueScan
Cancer Q-PCR arrays and IHC analysis of TMAs. However, we
observed a lack of transcript-protein correlation for the other
cancer types. While this is likely due to the use of unrelated tumor
samples in the transcript and protein analyses, we cannot rule out
that in certain tumors the expression of LEDGF/p75 transcript
does not correlate with protein expression. There are several
reports documenting this phenomenon for other cancer-associated
proteins [33,38–44]. For instance, integrative studies of transcript
and protein expression profiles in tumors and cancer cell lines
showed discordant protein and mRNA expression, revealing a
20%–65% concordance depending on the tumor type [41–43]. As
a specific example, transcript expression of the Pdc4 tumor
suppressor gene was found suppressed in tumors compared to
normal tissues, but the protein levels were elevated [39]. Likewise,
it was observed that in nasopharyngeal carcinomas, the LMP1
mRNA and protein expression levels did not correlate [44].
Factors leading to discordant transcript-protein correlation in
tumor cells include abnormal protein stabilization via protein-
protein interactions or post-translational modifications, differential
lifetimes of the mRNA and protein species, mRNA regulation by
miRNAs, differential regulation or processing of protein isoforms,
and other mechanisms not yet completely understood [38–44].
Our results highlight the need for analyzing simultaneously
LEDGF/p75 mRNA and protein expression in the same tumor
samples in future studies aimed at investigating the role of this pro-
survival protein in the progression of a specific cancer type, and its
potential value as a biomarker for tumor aggressiveness or
chemoresistance. Such studies should involve a large patient
sample size with complete annotated clinical data, as well as
inclusion of several disease-free normal control tissues. Indeed, a
limiting factor in our studies, and in most studies comparing gene
expression in tumor vs normal tissues, is that the control tissues
analyzed are often histologically/morphologically ‘‘normal’’ tissues
adjacent to the tumors. These ‘‘normal adjacent’’ tissues are
susceptible to ‘‘field cancerization’’, an effect that has been
documented in many human tumor types and that involves
molecular abnormalities in the normal adjacent tissue such as
increased expression of cancer-associated genes or proteins,
changes in gene methylation patterns, microsatellite alteration,
increased oxidative DNA damage and angiogenesis, and
TMPRSS2-ERG-fusions [45–50]. Field cancerization associated
with increased oxidative stress and inflammation in areas
surrounding the tumors could lead to upregulation of stress
response proteins such as LEDGF/p75 in the normal tissue
adjacent to the tumor, resulting in underestimation of the extent of
its overexpression in the tumors. Consistent with this notion, we
reported recently that the expression levels of the stress/
antioxidant proteins peroxiredoxins 3 and 4 in normal tissues
adjacent to prostate tumors are intermediate between tumor
tissues and non-diseased normal prostate tissues [33].
To our knowledge, this is the first comprehensive survey of the
expression of LEDGF/p75 transcript and protein in human
cancers. In summary, our results revealed a significant upregula-
tion of LEDGF/p75 (transcript or protein) in several cancer types,
Table 5. Summary table of the cross-platform analyses of
LEDGF/p75 transcript and protein expression in various
human tumor types as compared to corresponding normal
tissues.
Cancer type Oncomine Q-PCR Immunohistochemistry
Bladder X No data X
Breast qq X
Cervix q No data X
Colon qq q
Esophagus q No data X
Gall bladder No data No data X
Kidney q XX
Head and neck q No data X
Liver q X q
Lung q XX
Lymphoma q No data X
Ovary q XX
Pancreas q No data X
Prostate qq q
Rectum and anus q No data X
Salivary gland q No data X
Skin q No data X
Small Intestine No data No data X
Stomach q No data X
Thyroid No data qq
Uterus X No data q
q, Statistically significant (p,0.05) increase in LEDGF/p75 expression in tumors
versus normal tissues;
X, No statistically significant (p,0.05) change in LEDGF/p75 expression in
tumors versus normal tissues; No data, no datasets or tissues available.
doi:10.1371/journal.pone.0030132.t005
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malignancies (summarized in Table 5). Because our study was
limited by the lack of complete clinical and follow-up patient data
associated with the TMAs, the prognostic significance of LEDGF/
p75 overexpression in human cancer still remains unclear. Further
studies analyzing simultaneously both LEDGF/p75 transcript and
protein in the same tissues, using large patient cohorts with
complete clinical and follow-up data, are necessary to determine if
LEDGF/p75 upregulation correlates with tumor progression and
aggressiveness in a specific cancer type. Taken together, the results
presented here further establish LEDGF/p75 as a cancer-related
protein, and strengthen the rationale for investigating the
biological and clinical significance of its upregulation in human
tumors.
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